Cargando…
Toca 511 gene transfer and treatment with the prodrug, 5-fluorocytosine, promotes durable antitumor immunity in a mouse glioma model
BACKGROUND. Toca 511 (vocimagene amiretrorepvec) is a retroviral replicating vector encoding an optimized yeast cytosine deaminase (CD). Tumor-selective expression of CD converts the prodrug, 5-fluorocytosine (5-FC), into the active chemotherapeutic, 5-fluorouracil (5-FU). This therapeutic approach...
Autores principales: | Mitchell, Leah A., Lopez Espinoza, Fernando, Mendoza, Daniel, Kato, Yuki, Inagaki, Akihito, Hiraoka, Kei, Kasahara, Noriyuki, Gruber, Harry E., Jolly, Douglas J., Robbins, Joan M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5570153/ https://www.ncbi.nlm.nih.gov/pubmed/28387849 http://dx.doi.org/10.1093/neuonc/nox037 |
Ejemplares similares
-
Retroviral Replicating Vector Toca 511 (Vocimagene Amiretrorepvec) for Prodrug Activator Gene Therapy of Lung Cancer
por: Kushiya, Hiroki, et al.
Publicado: (2022) -
Retroviral replicating vector–mediated gene therapy achieves long-term
control of tumor recurrence and leads to durable anticancer immunity
por: Hiraoka, Kei, et al.
Publicado: (2017) -
Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector
por: Ostertag, Derek, et al.
Publicado: (2012) -
Radio-sensitization of gliomas by intracellular generation of 5-fluorouracil potentiates prodrug activator gene therapy with a retroviral replicating vector
por: Takahashi, Masamichi, et al.
Publicado: (2014) -
Targeted antitumor prodrug therapy using CNGRC-yCD fusion protein in combination with 5-fluorocytosine
por: Li, Jia-Je, et al.
Publicado: (2016)